EPIQ Capital Group

EPIQ Capital Group, LLC is a multi-family office and investment firm based in San Francisco, California. Established in 2017, the firm focuses on providing tailored wealth management and family office services to high net worth individuals and their families. EPIQ Capital Group aims to simplify the financial lives of its clients, which include prominent senior executives and founders of high-profile companies. The firm employs a range of analytical techniques, including charting, technical, cyclical, and fundamental analysis, to create investment portfolios that encompass public equity and fixed income markets. Additionally, it offers the launch of mutual funds to meet the diverse financial needs of its clientele. EPIQ Capital Group is committed to core values such as integrity, excellence, and growth, positioning itself as a trusted partner for ultra-high-net-worth clients.

Chad Boeding

Founder and CEO

21 past transactions

AheadComputing

Seed Round in 2025
AheadComputing is a technology company that designs and licenses high-performance microprocessor cores, along with related support services. Their focus is on RISC-V core intellectual property, offering scalable solutions for next-generation embedded systems. By providing efficient and scalable embedded systems, AheadComputing helps clients enhance performance, reduce power consumption, and accelerate time-to-market for their devices across diverse applications.

Zephyr AI

Series A in 2024
Zephyr AI is a healthcare technology company focused on transforming drug discovery and precision medicine. By leveraging large complex datasets and proprietary algorithms, Zephyr AI aims to redefine drug development and streamline clinical trials. The company collaborates with leading health systems, health insurance plans, and biotechnology innovators to enhance healthcare quality, improve patient outcomes, and reduce costs. Through its innovative approach, Zephyr AI seeks to address challenges in disease treatment and clinical decision support, ultimately contributing to advancements in the healthcare sector.

Tenstorrent

Venture Round in 2023
Tenstorrent Inc. is a technology company based in Toronto, Canada, with an additional office in Austin, Texas, founded in 2016. The company specializes in the development and manufacturing of application-specific integrated circuits (ASICs) tailored for machine learning and data processing tasks. Its hardware architecture is designed to support a range of applications, from battery-powered Internet of Things (IoT) devices to large-scale cloud servers, providing scalable solutions for deep learning. Tenstorrent's offerings enable developers and researchers in the artificial intelligence sector to enhance computational performance and adapt algorithms effectively, positioning the company as a key player in advancing AI technology.

Swift Navigation

Series D in 2022
Swift Navigation, Inc. is a technology company specializing in high-precision global positioning system (GPS) and global navigation satellite system (GNSS) solutions. Founded in 2012 and headquartered in San Francisco, California, with an additional location in Melbourne, Australia, the company aims to make accurate positioning technology more accessible and affordable. Swift Navigation offers a range of products, including the Piksi Multi GNSS Module and the ruggedized Duro Receiver, both providing centimeter-level accuracy through real-time kinematics (RTK) technology. Their offerings also include the Skylark cloud corrections service and the Starling GNSS positioning engine, which cater to various sectors such as automotive, agriculture, robotics, and unmanned aerial vehicles (UAVs). The company is recognized for defining a new category of low-cost, high-accuracy GNSS systems, delivering significantly better performance than conventional GPS systems. Swift Navigation's innovative solutions have been acknowledged by prestigious lists, reflecting its role in transforming industries through automation and enhanced navigation capabilities.

Spotlight Therapeutics

Series B in 2022
Spotlight Therapeutics is a biotechnology company based in Hayward, California, founded in 2017. It specializes in developing gene editing therapeutics that target specific cell populations directly within the body. The company's platform utilizes CRISPR technology to deliver programmable nucleases to selected cell types in vivo, enabling precise and selective gene editing. Spotlight Therapeutics focuses on creating next-generation treatments for various diseases, with initial programs in immuno-oncology, ophthalmology, and hematology.

Epirus

Series C in 2022
Epirus, Inc. is a technology company based in Hawthorne, California, specializing in the design and development of advanced defense systems that utilize artificial intelligence and directed energy. Founded in 2018, the company focuses on creating solid-state, software-defined high-power microwave solutions aimed at countering unmanned aircraft systems and other asymmetric threats. Its flagship product, ELECTROMAGNETIC PULSE, serves as a counter-infrastructure solution that can simultaneously target multiple threats, effectively neutralizing drones and swarms. By integrating AI and machine learning with advanced electronics, Epirus enhances the detection and tracking of objects of interest, offering innovative capabilities in electronic warfare and power management for both defense and commercial sectors.

SalioGen Therapeutics

Series B in 2022
SalioGen Therapeutics is a biotechnology company focused on developing innovative gene therapies for inherited disorders. Utilizing its proprietary Exact DNA Integration Technology (EDIT) platform, the company employs mammal-derived enzymes known as Saliogase to facilitate genome engineering. This approach allows for non-viral delivery of genes of any size, offering significant advantages in manufacturing and application. SalioGen's technology aims to provide safe, durable, and affordable solutions that could transform treatment options for patients with genetic conditions, while also enhancing the efficiency of cell therapy and biologics manufacturing within the healthcare sector.

VideoAmp

Series F in 2021
VideoAmp is a software and data company that develops an integrated platform aimed at transforming the advertising landscape by unifying traditional TV, streaming video, and digital media. Its innovative platform provides measurement and optimization tools that connect media exposures directly to an advertiser's sales, allowing for a more cohesive understanding of audience engagement. By facilitating transactions based on independent measurement as a multi-platform media currency, VideoAmp enables advertisers, agencies, and media sellers to align their strategies effectively. This approach not only optimizes brand marketing investments but also drives real business outcomes, creating efficiencies across various advertising channels.

Windfall

Series A in 2021
Windfall Data, established in 2016 and headquartered in San Francisco, specializes in determining the net worth of global households. The company provides actionable consumer financial data that is updated weekly, serving both nonprofit and for-profit organizations. This data helps over 400 organizations identify and engage their most valuable constituents. Windfall Data's platform utilizes various datasets and proprietary algorithms to offer insights for marketing, sales, and analytics, enabling businesses to prioritize consumers effectively. The company is supported by several venture capital firms including Bullpen Capital, Bonfire Ventures, Industry Ventures, TenOneTen Ventures, ValueStream Ventures, and Auren Hoffman.

Swift Navigation

Series C in 2021
Swift Navigation, Inc. is a technology company specializing in high-precision global positioning system (GPS) and global navigation satellite system (GNSS) solutions. Founded in 2012 and headquartered in San Francisco, California, with an additional location in Melbourne, Australia, the company aims to make accurate positioning technology more accessible and affordable. Swift Navigation offers a range of products, including the Piksi Multi GNSS Module and the ruggedized Duro Receiver, both providing centimeter-level accuracy through real-time kinematics (RTK) technology. Their offerings also include the Skylark cloud corrections service and the Starling GNSS positioning engine, which cater to various sectors such as automotive, agriculture, robotics, and unmanned aerial vehicles (UAVs). The company is recognized for defining a new category of low-cost, high-accuracy GNSS systems, delivering significantly better performance than conventional GPS systems. Swift Navigation's innovative solutions have been acknowledged by prestigious lists, reflecting its role in transforming industries through automation and enhanced navigation capabilities.

Lineage Logistics

Private Equity Round in 2020
Lineage Logistics is a leader in temperature-controlled supply chain and logistics, specializing in innovative, end-to-end solutions that enhance food safety and distribution efficiency. The company offers a wide range of services, including cold storage warehousing, automated warehousing, port-centric warehousing, sustainable warehousing, freight forwarding, drayage, and customs brokerage. By leveraging advanced technology and a comprehensive real estate network, Lineage aims to minimize supply chain waste and reduce environmental impact, thereby helping clients—from large corporations to smaller family-owned businesses—maintain the integrity of their temperature-sensitive products. Recognized for its innovative approach, Lineage has been acknowledged as a top data science company and has received accolades for its contributions to the logistics industry.

Lucira Health

Series C in 2020
Lucira Health, Inc. is a medical technology company that specializes in the development and commercialization of innovative infectious disease test kits. Founded in 2013 and based in Emeryville, California, Lucira has created a consumer-friendly, single-use testing platform that delivers centralized-laboratory-accurate molecular testing. Their flagship product is a disposable COVID-19 test kit that can be used at home, featuring a mobile application that connects users to treatment options. The kit is powered by two AA batteries and is compact enough to fit in the palm of a hand. Additionally, Lucira has developed a 2-in-1 lab testing solution that can determine if viral respiratory symptoms are due to COVID-19 or the flu, enhancing the accessibility and convenience of viral testing for consumers.

SpotOn

Series B in 2020
SpotOn is a technology company founded in 2017 by Doron Friedman, Matt Hyman, and Zach Hyman, headquartered in San Francisco, California. The company specializes in providing innovative software and payment solutions tailored for small and midsize businesses. SpotOn offers a comprehensive, cloud-based platform that includes tools for payments, point-of-sale systems, marketing, website development, online ordering, appointments, eCommerce, digital loyalty, and review management. By integrating these services, SpotOn aims to enhance operational efficiency and customer engagement for its clients. The company's mission is to empower businesses by delivering high-quality solutions at fair prices, supported by personalized local service.

Applied Molecular Transport

Series C in 2019
Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, focused on developing oral biologic product candidates to address autoimmune, inflammatory, metabolic, and other diseases. Utilizing its proprietary technology platform, the company aims to leverage natural cellular trafficking pathways for the efficient transport of therapeutics across the intestinal epithelium barrier. Its lead product candidate, AMT-101, is an oral gastrointestinal-selective interleukin 10 that has successfully completed a Phase 1b clinical trial for ulcerative colitis. Applied Molecular Transport is also advancing AMT-126, an oral fusion of rhIL-22 targeting intestinal epithelium barrier function defects. The company's pipeline includes various oral biologic modalities, such as peptides, proteins, antibodies, and RNA therapeutics, designed for both localized gastrointestinal treatment and systemic circulation, emphasizing patient-friendly tablet and capsule forms.

Lucira Health

Series B in 2019
Lucira Health, Inc. is a medical technology company that specializes in the development and commercialization of innovative infectious disease test kits. Founded in 2013 and based in Emeryville, California, Lucira has created a consumer-friendly, single-use testing platform that delivers centralized-laboratory-accurate molecular testing. Their flagship product is a disposable COVID-19 test kit that can be used at home, featuring a mobile application that connects users to treatment options. The kit is powered by two AA batteries and is compact enough to fit in the palm of a hand. Additionally, Lucira has developed a 2-in-1 lab testing solution that can determine if viral respiratory symptoms are due to COVID-19 or the flu, enhancing the accessibility and convenience of viral testing for consumers.

Swift Navigation

Series C in 2019
Swift Navigation, Inc. is a technology company specializing in high-precision global positioning system (GPS) and global navigation satellite system (GNSS) solutions. Founded in 2012 and headquartered in San Francisco, California, with an additional location in Melbourne, Australia, the company aims to make accurate positioning technology more accessible and affordable. Swift Navigation offers a range of products, including the Piksi Multi GNSS Module and the ruggedized Duro Receiver, both providing centimeter-level accuracy through real-time kinematics (RTK) technology. Their offerings also include the Skylark cloud corrections service and the Starling GNSS positioning engine, which cater to various sectors such as automotive, agriculture, robotics, and unmanned aerial vehicles (UAVs). The company is recognized for defining a new category of low-cost, high-accuracy GNSS systems, delivering significantly better performance than conventional GPS systems. Swift Navigation's innovative solutions have been acknowledged by prestigious lists, reflecting its role in transforming industries through automation and enhanced navigation capabilities.

Lucira Health

Series B in 2019
Lucira Health, Inc. is a medical technology company that specializes in the development and commercialization of innovative infectious disease test kits. Founded in 2013 and based in Emeryville, California, Lucira has created a consumer-friendly, single-use testing platform that delivers centralized-laboratory-accurate molecular testing. Their flagship product is a disposable COVID-19 test kit that can be used at home, featuring a mobile application that connects users to treatment options. The kit is powered by two AA batteries and is compact enough to fit in the palm of a hand. Additionally, Lucira has developed a 2-in-1 lab testing solution that can determine if viral respiratory symptoms are due to COVID-19 or the flu, enhancing the accessibility and convenience of viral testing for consumers.

Tenstorrent

Series B in 2019
Tenstorrent Inc. is a technology company based in Toronto, Canada, with an additional office in Austin, Texas, founded in 2016. The company specializes in the development and manufacturing of application-specific integrated circuits (ASICs) tailored for machine learning and data processing tasks. Its hardware architecture is designed to support a range of applications, from battery-powered Internet of Things (IoT) devices to large-scale cloud servers, providing scalable solutions for deep learning. Tenstorrent's offerings enable developers and researchers in the artificial intelligence sector to enhance computational performance and adapt algorithms effectively, positioning the company as a key player in advancing AI technology.

Applied Molecular Transport

Series B in 2018
Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, focused on developing oral biologic product candidates to address autoimmune, inflammatory, metabolic, and other diseases. Utilizing its proprietary technology platform, the company aims to leverage natural cellular trafficking pathways for the efficient transport of therapeutics across the intestinal epithelium barrier. Its lead product candidate, AMT-101, is an oral gastrointestinal-selective interleukin 10 that has successfully completed a Phase 1b clinical trial for ulcerative colitis. Applied Molecular Transport is also advancing AMT-126, an oral fusion of rhIL-22 targeting intestinal epithelium barrier function defects. The company's pipeline includes various oral biologic modalities, such as peptides, proteins, antibodies, and RNA therapeutics, designed for both localized gastrointestinal treatment and systemic circulation, emphasizing patient-friendly tablet and capsule forms.

Quince Therapeutics

Series B in 2018
Quince Therapeutics is a preclinical stage biopharmaceutical company dedicated to developing innovative precision therapeutics for debilitating and rare diseases. The company has created a unique bone-targeting drug platform that enables the precise delivery of small molecules, peptides, or large molecules directly to the site of bone fractures and diseases. This targeted approach aims to enhance healing rates while minimizing off-target safety concerns often associated with non-targeted therapies. Quince Therapeutics focuses on addressing impairments related to strength, functionality, debilitating pain, and other serious health challenges.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.